Tisagenlecleucel (CTL019), a CAR T-cell agent, was approved for acute lymphoblastic leukemia (ALL) treatment in children and young adults last year after positive results from the ELIANA trial (NCT02435849). In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Stephan Grupp, MD, PhD, of the Childrens Hospital of Philadelphia, Philadelphia, PA, discusses data from this trial, as well as the current landscape of CAR T-cell therapy in hematological oncology. He also speaks about future aims for this field, including the goal of cultivating long-term disease management with CAR T-cells and without bone marrow transplant.
Tisagenlecleucel in ALL: follow-up data and insights
